VJOncology is committed to improving our service to you

ASCO 2020 | Safety outcomes of darolutamide vs apalutamide and enzalutamide in nmCRPC

VJOncology is committed to improving our service to you

Neal Shore

Neal Shore, MD, Carolina Urologic Research Center, Myrtle Beach, SC, discusses the safety outcomes of darolutamide versus apalutamide and enzalutamide in non-metastatic castration-resistant prostate cancer (nmCRPC) using matching-adjusted indirect comparisons. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter